Učitavanje...

Prevalence and determinants of non-adherence to Imatinib in the first 3-months treatment among newly diagnosed Ethiopian’s with chronic myeloid leukemia

OBJECTIVES: Imatinib has shown to be highly efficacious in the treatment of chronic myeloid leukemia (CML) but continuous dosing and patient adherence is essential treatment success. The study aimed to assess prevalence and reasons for non-adherence to Imatinib in newly diagnosed patients with CML i...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:PLoS One
Glavni autori: Mulu Fentie, Atalay, Tadesse, Fishatsion, Engidawork, Ephrem, Gebremedhin, Am
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2019
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6405163/
https://ncbi.nlm.nih.gov/pubmed/30845227
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0213557
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!